Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-Targeting CAR-NK Cells in Recurrent or Progressive Glioblastoma or High-Grade Glioma
NCT07480941Phase 1Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EB-DT-CAR-NK in glioblastoma (GBM) and glioma (3 arms), sponsored by Biotech Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 28 days and Maximum Tolerated Dose at 12 months. Started Feb 2026; status: recruiting.
02
Drugs
EB-DT-CAR-NK
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT07480941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480941.